VetInject A/SAktiv

The company’s activity level has been fairly low as a result of the other activities in Injecto Group A/S, where Injecto Group A/S took over VetInject A/S back in 2023.The company still expects to base its business activities on the following basis and believes that the positive developments with respect to Injecto Group A/S’ subsidiary, Injecto A/S, which company focuses on primary packaging for human pharma, will contribute significantly to VetInject:Sales of lubrigone plunger stoppers included in pre-filled syringes (“PFS”) with preparations for animals with emphasis on dogs, cats and horses to syringe manufacturers, where such syringes are manufactured by other companies or by a subsidiary within the Injecto Group and the stoppers will be implemented as an integrated part of their product.Sublicense sales of lubrigone plunger stoppers and/or to companies producing veterinarian pharma.The plunger stoppers mentioned in points 1 and 2 above can be delivered by the licensor’s and parent company’s subsidiary, Injecto A/S. In this connection the company can benefit from the contacts established by the licensor and parent company and its associated companies with the pharmaceutical industry, where some of those contacts in addition to their production of medicinal preparations for humans also produce medicinal preparations for animals. The licensor's and parent company’s subsidiary, Injecto A/S’, established production line for plunger stoppers for 0.5 ml PFS in ISO in addition

The income statement for 2024/25 shows a loss of DKK 171,903 against a loss of DKK 240,531 last year, and the balance sheet at 31 August 2025 shows equity of DKK 52,731. The company’s financial result reflects that the company is in the initialisation of its commercial activities.The decision to await the development of the cooperation between the licensor and PATH mentioned above and the licensor’s decision to take over the company has led to the postponement of a supplementary capitalisation of the company.Notwithstanding the foregoing, it is the intention of the parent company to secure that the company over time will be a fully operational company, which in principle is independent of the parent company apart from the license contract on arm’s length basis.As a part of the strategic fit between Injecto Group A/S and VetInject A/S it is expected that a key person with the right skills in due time will be employed as the responsible person for the build-up of this interesting business area, based on Injecto Group A/S’ patented technologies. During the year we have been in contact with one potential candidate, who will also be able to attract one or more partners within the veterinarian industry, where an investment from one of the candidates could be an option.Due to the ongoing natural disasters and increase in zoonotic diseases we believe in a strong future for VetInject A/S and it is merely a question of timing and dedication of the right resources for the initialisation

Uddrag af ledelsesberetningen i den seneste årsrapport.